Healthcare

NanoViricides Reports Form 10-Q Filing as NV-387 Enters Phase II Ebola and Mpox Trials

NanoViricides has filed its quarterly report for the period ended September 30, 2026 and reported progress in two Phase II clinical trials of NV-387 Oral Gummies.

Published:
Reading Time
4 min

NanoViricides, Inc. (NYSE American: NNVC) has filed its quarterly report for the fiscal quarter ended September 30, 2026, while reporting that its NV-387 Oral Gummies candidate has entered separate Phase II clinical trials for Ebola Bundibugyo Virus Disease and Mpox.

The company said it submitted Form 10-Q to the Securities and Exchange Commission on Monday, November 16, 2026.

#NV-387 trials in the Democratic Republic of the Congo

Enrollment in the Phase II Ebola Bundibugyo Virus Disease trial began on September 23, 2026. NanoViricides said there is no drug or vaccine licensed for the novel Ebola Bundibugyo strain.

The company reported that ACOREP, the regulatory agency in the Democratic Republic of the Congo, approved the Ebola trial in the first week of August, 2026. NanoViricides has since been preparing Ebola Treatment Centers and an on-site clinical pathology laboratory equipped for quantitative reverse transcriptase PCR analysis.

NanoViricides said it has funded the Ebola trial solely on its own to date.

The separate Phase II Mpox trial began with the opening of a clinical trial site on September 23, 2026. During the quarter, the company said it continued work on a remote site in the Democratic Republic of the Congo for the study.

#Additional development plans

NanoViricides intends to engage in a Phase II clinical trial of NV-387 for measles. It also plans to advance the candidate for measles treatment and prophylaxis in the United States and said it intends to seek non-dilutive funding, including US government grants.

The company said its wider plans include bringing the Ebola and Mpox trials under US FDA Investigational New Drug applications, pursuing Phase II trials for Viral Acute and Severe Acute Respiratory Infections and Severe Acute Respiratory Infections, and preparing a pre-IND filing for a Phase II RSV trial in the USA.

NanoViricides also reported that the US FDA granted NV-387 an Orphan Drug Designation for measles on or about April 27, 2026, and a Rare Pediatric Disease designation in May, 2026.

#Pediatric toxicology study

The company said it had completed a repeated-dose toxicology study in juvenile mouse pups that were 4-day old. Under the conditions of the study, the No Observed Adverse Effect Level was 1,230 mg/kg per dose administered three times daily, or 3,690 mg/kg/day, with total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing period.

NanoViricides said 1,230 mg/kg per dose was the highest dose tested, meaning a Maximum Tolerable Dose could not be estimated in the study.

#Financial position and funding constraints

As of September 30, 2026, NanoViricides reported approximately $2.98 Million in cash and cash equivalent current assets, approximately $9.56 Million in total Assets and approximately $3.1 Million in total current liabilities. Net Property and Equipment assets after depreciation were approximately $6.28 Million.

Net cash utilised during the three months ended September 30, 2026 was approximately $3.64 Million. The company said this included certain non-recurring expenditures, including research and development spending for the Phase II clinical trials.

NanoViricides reported that it did not have sufficient funding in hand to continue operations through November 16, 2027, for all of its planned objectives. It said it currently has sufficient funding to execute and complete the Phase II Mpox and Ebola trials in the Democratic Republic of the Congo according to its plans and projections, while continuing to adjust its business plan to match available funding.

The company said it has access to an At-The-Market common stock facility under a shelf registration, with D. Boral Capital, LLC acting as sales agent. It also reported that an additional gross cash financing of $6.25 Million would result if and when Series A warrants from the November, 2025 financing are exercised.

NanoViricides further said it has access to a $3 million line of credit provided by founder and President Dr. Anil Diwan. No funds had been drawn on that facility as of the report.

#Company and drug candidate

NanoViricides describes itself as a clinical stage company developing special purpose nanomaterials for antiviral therapy. Its lead candidate, NV-387, is being developed for a range of viral diseases, including RSV, COVID, Long COVID, Influenza, Mpox, Smallpox and measles.

The company stated that NV-387 is a clinical stage drug candidate that has not been licensed or approved for any indication at present. NanoViricides also said it cannot project an exact date for filing an IND for any of its drugs because it depends on external collaborators and consultants.

The company said pharmaceutical development is extremely lengthy and requires substantial capital. It also stated that there can be no assurance its candidates will demonstrate sufficient effectiveness and safety for human clinical development or become successful pharmaceutical products.

#Key Takeaways

  • NanoViricides filed its Form 10-Q for the fiscal quarter ended September 30, 2026 on Monday, November 16, 2026.
  • NV-387 Oral Gummies entered separate Phase II trials for Ebola Bundibugyo Virus Disease and Mpox in the Democratic Republic of the Congo.
  • The company reported approximately $2.98 Million in cash and cash equivalent current assets and approximately $3.1 Million in total current liabilities as of September 30, 2026.
  • NanoViricides said it has sufficient funding for the two DRC Phase II trials but not for all planned objectives through November 16, 2027.
  • The company intends to pursue a Phase II measles trial and additional development and regulatory activities for NV-387.

Original source: Read original article

Frequently Asked Questions